Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 309469, 16 pages
http://dx.doi.org/10.1155/2008/309469
Review Article

PPAR 𝜸 and MEK Interactions in Cancer

1Department of Medicine II, Klinikum Rechts der Isar, Technical University, 81675 Munich, Germany
2Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel

Received 4 March 2008; Accepted 29 April 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Elke Burgermeister and Rony Seger. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. D. Rosen and B. M. Spiegelman, “PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth,” Journal of Biological Chemistry, vol. 276, no. 41, pp. 37731–37734, 2001. View at Google Scholar
  2. M. Lehrke and M. A. Lazar, “The many faces of PPARγ,” Cell, vol. 123, no. 6, pp. 993–999, 2005. View at Publisher · View at Google Scholar
  3. W.-W. Lin and M. Karin, “A cytokine-mediated link between innate immunity, inflammation, and cancer,” The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1175–1183, 2007. View at Publisher · View at Google Scholar
  4. M. L. Slattery, K. Curtin, R. Wolff et al., “PPAR? and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States),” Cancer Causes & Control, vol. 17, no. 3, pp. 239–249, 2006. View at Publisher · View at Google Scholar
  5. J. M. Zmuda, F. Modugno, J. L. Weissfeld et al., “Peroxisome proliferator-activated receptor-? polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction,” Oncology, vol. 70, no. 3, pp. 185–189, 2006. View at Publisher · View at Google Scholar
  6. R. Schiel, W. Beltschikow, T. Steiner, and G. Stein, “Diabetes, insulin, and risk of cancer,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 28, no. 3, pp. 169–175, 2006. View at Publisher · View at Google Scholar
  7. M. Khan, M. Mori, Y. Fujino et al., “Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study,” Asian Pacific Journal of Cancer Prevention, vol. 7, no. 2, pp. 253–259, 2006. View at Google Scholar
  8. A. Czyżyk and Z. X. Szczepanik, “Diabetes mellitus and cancer,” European Journal of Internal Medicine, vol. 11, no. 5, pp. 245–252, 2000. View at Publisher · View at Google Scholar
  9. R. Kostadinova, W. Wahli, and L. Michalik, “PPARs in diseases: control mechanisms of inflammation,” Current Medicinal Chemistry, vol. 12, no. 25, pp. 2995–3009, 2005. View at Publisher · View at Google Scholar
  10. B. P. Kota, T. H.-W. Huang, and B. D. Roufogalis, “An overview on biological mechanisms of PPARs,” Pharmacological Research, vol. 51, no. 2, pp. 85–94, 2005. View at Publisher · View at Google Scholar
  11. B. Charbonnel, “Glitazones in the treatment of diabetes mellitus: clinical outcomes in large scale clinical trials,” Fundamental & Clinical Pharmacology, vol. 21, supplement 2, pp. 19–20, 2007. View at Publisher · View at Google Scholar
  12. J. A. Dormandy, B. Charbonnel, D. J. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial,” The Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at Publisher · View at Google Scholar
  13. F. Blaschke, R. Spanheimer, M. Khan, and R. E. Law, “Vascular effects of TZDs: new implications,” Vascular Pharmacology, vol. 45, no. 1, pp. 3–18, 2006. View at Publisher · View at Google Scholar
  14. L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome-proliferator-activated receptors and cancers: complex stories,” Nature Reviews Cancer, vol. 4, no. 1, pp. 61–70, 2004. View at Publisher · View at Google Scholar
  15. A. Galli, T. Mello, E. Ceni, E. Surrenti, and C. Surrenti, “The potential of antidiabetic thiazolidinediones for anticancer therapy,” Expert Opinion on Investigational Drugs, vol. 15, no. 9, pp. 1039–1049, 2006. View at Publisher · View at Google Scholar
  16. C. Koro, S. Barrett, and N. Qizilbash, “Cancer risks in thiazolidinedione users compared to other anti-diabetic agents,” Pharmacoepidemiology and Drug Safety, vol. 16, no. 5, pp. 485–492, 2007. View at Publisher · View at Google Scholar
  17. M. E. Ramos-Nino, C. D. MacLean, and B. Littenberg, “Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System,” BMC Medicine, vol. 5, article 17, pp. 1–7, 2007. View at Publisher · View at Google Scholar
  18. R. Govindarajan, L. Ratnasinghe, D. L. Simmons et al., “Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1476–1481, 2007. View at Publisher · View at Google Scholar
  19. C. M. Ulrich, J. Bigler, and J. D. Potter, “Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics,” Nature Reviews Cancer, vol. 6, no. 2, pp. 130–140, 2006. View at Publisher · View at Google Scholar
  20. R. Seger and E. G. Krebs, “The MAPK signaling cascade,” The FASEB Journal, vol. 9, no. 9, pp. 726–735, 1995. View at Google Scholar
  21. S. Yoon and R. Seger, “The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions,” Growth Factors, vol. 24, no. 1, pp. 21–44, 2006. View at Publisher · View at Google Scholar
  22. D. Chuderland and R. Seger, “Protein-protein interactions in the regulation of the extracellular signal-regulated kinase,” Molecular Biotechnology, vol. 29, no. 1, pp. 57–74, 2005. View at Publisher · View at Google Scholar
  23. Y. D. Shaul and R. Seger, “The MEK/ERK cascade: from signaling specificity to diverse functions,” Biochimica et Biophysica Acta, vol. 1773, no. 8, pp. 1213–1226, 2007. View at Publisher · View at Google Scholar
  24. S. Torii, T. Yamamoto, Y. Tsuchiya, and E. Nishida, “ERK MAP kinase in G1 cell cycle progression and cancer,” Cancer Science, vol. 97, no. 8, pp. 697–702, 2006. View at Publisher · View at Google Scholar
  25. P. J. Roberts and C. J. Der, “Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer,” Oncogene, vol. 26, no. 22, pp. 3291–3310, 2007. View at Publisher · View at Google Scholar
  26. J. A. McCubrey, L. S. Steelman, W. H. Chappell et al., “Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance,” Biochimica et Biophysica Acta, vol. 1773, no. 8, pp. 1263–1284, 2007. View at Publisher · View at Google Scholar
  27. Y. Alvarado and F. J. Giles, “Ras as a therapeutic target in hematologic malignancies,” Expert Opinion on Emerging Drugs, vol. 12, no. 2, pp. 271–284, 2007. View at Publisher · View at Google Scholar
  28. M. A. Morgan, A. Ganser, and C. W. M. Reuter, “Targeting the RAS signaling pathway in malignant hematologic diseases,” Current Drug Targets, vol. 8, no. 2, pp. 217–235, 2007. View at Publisher · View at Google Scholar
  29. R. T. Nolte, G. B. Wisely, S. Westin et al., “Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-?,” Nature, vol. 395, no. 6698, pp. 137–143, 1998. View at Publisher · View at Google Scholar
  30. E. Burgermeister, D. Chuderland, T. Hanoch, M. Meyer, M. Liscovitch, and R. Seger, “Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor γ,” Molecular and Cellular Biology, vol. 27, no. 3, pp. 803–817, 2007. View at Publisher · View at Google Scholar
  31. E. Papageorgiou, N. Pitulis, P. Msaouel, P. Lembessis, and M. Koutsilieris, “The non-genomic crosstalk between PPAR-γ ligands and ERK1/2 in cancer cell lines,” Expert Opinion on Therapeutic Targets, vol. 11, no. 8, pp. 1071–1085, 2007. View at Publisher · View at Google Scholar
  32. S. Miard and L. Fajas, “Atypical transcriptional regulators and cofactors of PPARγ,” International Journal of Obesity, vol. 29, supplement 1, pp. S10–S12, 2005. View at Publisher · View at Google Scholar
  33. C. Grommes, G. E. Landreth, and M. T. Heneka, “Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists,” The Lancet Oncology, vol. 5, no. 7, pp. 419–429, 2004. View at Publisher · View at Google Scholar
  34. J. Lu, K. Imamura, S. Nomura et al., “Chemopreventive effect of peroxisome proliferator-activated receptor ? on gastric carcinogenesis in mice,” Cancer Research, vol. 65, no. 11, pp. 4769–4774, 2005. View at Publisher · View at Google Scholar
  35. C. J. Nicol, M. Yoon, J. M. Ward et al., “PPAR? influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis,” Carcinogenesis, vol. 25, no. 9, pp. 1747–1755, 2004. View at Publisher · View at Google Scholar
  36. G. D. Girnun, W. M. Smith, S. Drori et al., “APC-dependent suppression of colon carcinogenesis by PPAR?,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 21, pp. 13771–13776, 2002. View at Publisher · View at Google Scholar
  37. A. Meirhaeghe and P. Amouyel, “Impact of genetic variation of PPARγ in humans,” Molecular Genetics and Metabolism, vol. 83, no. 1-2, pp. 93–102, 2004. View at Publisher · View at Google Scholar
  38. P. Sarraf, E. Mueller, W. M. Smith et al., “Loss-of-function mutations in PPAR? associated with human colon cancer,” Molecular Cell, vol. 3, no. 6, pp. 799–804, 1999. View at Publisher · View at Google Scholar
  39. T. Tahara, T. Arisawa, T. Shibata et al., “Influence of peroxisome proliferator-activated receptor (PPAR)? Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese,” Digestive Diseases and Sciences, vol. 53, no. 3, pp. 614–621, 2008. View at Publisher · View at Google Scholar
  40. C. Diradourian, J. Girard, and J.-P. Pégorier, “Phosphorylation of PPARs: from molecular characterization to physiological relevance,” Biochimie, vol. 87, no. 1, pp. 33–38, 2005. View at Publisher · View at Google Scholar
  41. C. Rochette-Egly, “Nuclear receptors: integration of multiple signalling pathways through phosphorylation,” Cellular Signalling, vol. 15, no. 4, pp. 355–366, 2003. View at Publisher · View at Google Scholar
  42. D. Genini and C. V. Catapano, “Control of peroxisome proliferator-activated receptor fate by the ubiquitin-proteasome system,” Journal of Receptors and Signal Transduction, vol. 26, no. 5-6, pp. 679–692, 2006. View at Publisher · View at Google Scholar
  43. Z. E. Floyd and J. M. Stephens, “Interferon-γ-mediated activation and ubiquitin-proteasome-dependent degradation of PPARγ in adipocytes,” Journal of Biological Chemistry, vol. 277, no. 6, pp. 4062–4068, 2002. View at Publisher · View at Google Scholar
  44. K. A. Burns and J. P. Vanden Heuvel, “Modulation of PPAR activity via phosphorylation,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 952–960, 2007. View at Publisher · View at Google Scholar
  45. S. M. Rangwala, B. Rhoades, J. S. Shapiro et al., “Genetic modulation of PPAR? phosphorylation regulates insulin sensitivity,” Developmental Cell, vol. 5, no. 4, pp. 657–663, 2003. View at Publisher · View at Google Scholar
  46. T. Hosooka, T. Noguchi, K. Kotani et al., “Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-? phosphorylation,” Nature Medicine, vol. 14, no. 2, pp. 188–193, 2008. View at Publisher · View at Google Scholar
  47. L. Amazit, L. Pasini, A. T. Szafran et al., “Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation,” Molecular and Cellular Biology, vol. 27, no. 19, pp. 6913–6932, 2007. View at Publisher · View at Google Scholar
  48. C. N. Johnstone, P. S. Mongroo, A. S. Rich et al., “Parvin-ß inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor gamma 1 phosphorylation,” Molecular and Cellular Biology, vol. 28, no. 2, pp. 687–704, 2008. View at Publisher · View at Google Scholar
  49. C. Giaginis, A. Margeli, and S. Theocharis, “Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis,” Expert Opinion on Investigational Drugs, vol. 16, no. 10, pp. 1561–1572, 2007. View at Publisher · View at Google Scholar
  50. D. L. Feinstein, A. Spagnolo, C. Akar et al., “Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?” Biochemical Pharmacology, vol. 70, no. 2, pp. 177–188, 2005. View at Publisher · View at Google Scholar
  51. O. S. Gardner, B. J. Dewar, and L. M. Graves, “Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling,” Molecular Pharmacology, vol. 68, no. 4, pp. 933–941, 2005. View at Publisher · View at Google Scholar
  52. C. M. Revankar, D. F. Cimino, L. A. Sklar, J. B. Arterburn, and E. R. Prossnitz, “A transmembrane intracellular estrogen receptor mediates rapid cell signaling,” Science, vol. 307, no. 5715, pp. 1625–1630, 2005. View at Publisher · View at Google Scholar
  53. M. Watanabe, S. M. Houten, C. Mataki et al., “Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation,” Nature, vol. 439, no. 7075, pp. 484–489, 2006. View at Publisher · View at Google Scholar
  54. A. J. Brown, S. Jupe, and C. P. Briscoe, “A family of fatty acid binding receptors,” DNA and Cell Biology, vol. 24, no. 1, pp. 54–61, 2005. View at Publisher · View at Google Scholar
  55. Y. Itoh, Y. Kawamata, M. Harada et al., “Free fatty acids regulate insulin secretion from pancreatic ß cells through GPR40,” Nature, vol. 422, no. 6928, pp. 173–176, 2003. View at Publisher · View at Google Scholar
  56. Y. Itoh and S. Hinuma, “GPR40, a free fatty acid receptor on pancreatic β cells, regulates insulin secretion,” Hepatology Research, vol. 33, no. 2, pp. 171–173, 2005. View at Publisher · View at Google Scholar
  57. S. Hardy, G. G. St-Onge, É. Joly, Y. Langelier, and M. Prentki, “Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40,” Journal of Biological Chemistry, vol. 280, no. 14, pp. 13285–13291, 2005. View at Publisher · View at Google Scholar
  58. K. Kotarsky, N. E. Nilsson, E. Flodgren, C. Owman, and B. Olde, “A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs,” Biochemical and Biophysical Research Communications, vol. 301, no. 2, pp. 406–410, 2003. View at Publisher · View at Google Scholar
  59. M. Kampa and E. Castanas, “Membrane steroid receptor signaling in normal and neoplastic cells,” Molecular and Cellular Endocrinology, vol. 246, no. 1-2, pp. 76–82, 2006. View at Publisher · View at Google Scholar
  60. J. G. Greger, N. Fursov, N. Cooch et al., “Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase,” Molecular and Cellular Biology, vol. 27, no. 5, pp. 1904–1913, 2007. View at Publisher · View at Google Scholar
  61. C.-W. Wong, C. McNally, E. Nickbarg, B. S. Komm, and B. J. Cheskis, “Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 23, pp. 14783–14788, 2002. View at Publisher · View at Google Scholar
  62. A. Ptak-Belowska, M. W. Pawlik, G. Krzysiek-Mączka, T. Brzozowski, and W. W. Pawlik, “Transcriptional upregulation of gastrin in response to peroxisome proliferator-activated receptor gamma agonist triggers cell survival pathways,” Journal of Physiology and Pharmacology, vol. 58, no. 4, pp. 793–801, 2007. View at Google Scholar
  63. L. Tencer, E. Burgermeister, M. P. Ebert, and M. Liscovitch, “Rosiglitazone induces caveolin-1 by PPARγ-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance,” Anticancer Research, vol. 28, no. 2A, pp. 895–906, 2008. View at Google Scholar
  64. K.-H. Kim, Y. S. Cho, J.-M. Park, S.-O. Yoon, K.-W. Kim, and A.-S. Chung, “Pro-MMP-2 activation by the PPARγ agonist, ciglitazone, induces cell invasion through the generation of ROS and the activation of ERK,” FEBS Letters, vol. 581, no. 17, pp. 3303–3310, 2007. View at Publisher · View at Google Scholar
  65. J.-A. Kim, K.-S. Park, H.-I. Kim et al., “Troglitazone activates p21Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells,” Cancer Letters, vol. 179, no. 2, pp. 185–195, 2002. View at Publisher · View at Google Scholar
  66. A. Masamune, K. Satoh, Y. Sakai, M. Yoshida, A. Satoh, and T. Shimosegawa, “Ligands of peroxisome proliferator-activated receptor-gamma induce apoptosis in AR42J cells,” Pancreas, vol. 24, no. 2, pp. 130–138, 2002. View at Publisher · View at Google Scholar
  67. S. Han and J. Roman, “Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways,” Molecular Cancer Therapeutics, vol. 5, no. 2, pp. 430–437, 2006. View at Publisher · View at Google Scholar
  68. M. Li, T. W. Lee, A. P. C. Yim, T. S. K. Mok, and G. G. Chen, “Apoptosis induced by troglitazone is both peroxisome proliterator-activated receptor-γ- and ERK-dependent in human non-small lung cancer cells,” Journal of Cellular Physiology, vol. 209, no. 2, pp. 428–438, 2006. View at Publisher · View at Google Scholar
  69. K. Hashimoto, B. J. Farrow, and B. M. Evers, “Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell line MIA PaCa-2,” Pancreas, vol. 28, no. 2, pp. 153–159, 2004. View at Publisher · View at Google Scholar
  70. C. L. Bos, D. J. Richel, T. Ritsema, M. P. Peppelenbosch, and H. H. Versteeg, “Prostanoids and prostanoid receptors in signal transduction,” The International Journal of Biochemistry & Cell Biology, vol. 36, no. 7, pp. 1187–1205, 2004. View at Publisher · View at Google Scholar
  71. D. S. Straus and C. K. Glass, “Cyclopentenone prostaglandins: new insights on biological activities and cellular targets,” Medicinal Research Reviews, vol. 21, no. 3, pp. 185–210, 2001. View at Publisher · View at Google Scholar
  72. W. F. Stenson, “Prostaglandins and epithelial response to injury,” Current Opinion in Gastroenterology, vol. 23, no. 2, pp. 107–110, 2007. View at Publisher · View at Google Scholar
  73. E.-H. Kim, H.-K. Na, and Y.-J. Surh, “Upregulation of VEGF by 15-deoxy-Δ12,14-prostaglandin J2 via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells,” Annals of the New York Academy of Sciences, vol. 1090, pp. 375–384, 2006. View at Publisher · View at Google Scholar
  74. A.-M. Lefebvre, I. Chen, P. Desreumaux et al., “Activation of the peroxisome proliferator-activated receptor ? promotes the development of colon tumors in C57BL/6J-APCMin/+ mice,” Nature Medicine, vol. 4, no. 9, pp. 1053–1057, 1998. View at Publisher · View at Google Scholar
  75. E. Saez, P. Tontonoz, M. C. Nelson et al., “Activators of the nuclear receptor PPAR? enhance colon polyp formation,” Nature Medicine, vol. 4, no. 9, pp. 1058–1061, 1998. View at Publisher · View at Google Scholar
  76. M. V. Pino, M. F. Kelley, and Z. Jayyosi, “Promotion of colon tumors in C57BL/6J-APCmin/+ mice by thiazolidinedione PPARγ agonists and a structurally unrelated PPARγ agonist,” Toxicologic Pathology, vol. 32, no. 1, pp. 58–63, 2004. View at Publisher · View at Google Scholar
  77. K. Yang, K.-H. Fan, S. A. Lamprecht et al., “Peroxisome proliferator-activated receptor ? agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638N/+MIh+/- double mutant mice,” International Journal of Cancer, vol. 116, no. 4, pp. 495–499, 2005. View at Publisher · View at Google Scholar
  78. L. D. Yee, N. Williams, P. Wen et al., “Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers,” Clinical Cancer Research, vol. 13, no. 1, pp. 246–252, 2007. View at Publisher · View at Google Scholar
  79. E. Kebebew, M. Peng, E. Reiff et al., “A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer,” Surgery, vol. 140, no. 6, pp. 960–967, 2006. View at Publisher · View at Google Scholar
  80. F. L. Egerod, H. S. Nielsen, L. Iversen, I. Thorup, T. Storgaard, and M. B. Oleksiewicz, “Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo,” Biomarkers, vol. 10, no. 4, pp. 295–309, 2005. View at Publisher · View at Google Scholar
  81. M. B. Oleksiewicz, I. Thorup, H. S. Nielsen et al., “Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo,” Toxicologic Pathology, vol. 33, no. 5, pp. 552–560, 2005. View at Publisher · View at Google Scholar
  82. P. Balakumar, M. Rose, S. S. Ganti, P. Krishan, and M. Singh, “PPAR dual agonists: are they opening Pandora's Box?” Pharmacological Research, vol. 56, no. 2, pp. 91–98, 2007. View at Publisher · View at Google Scholar
  83. H. Hellmold, H. Zhang, U. Andersson et al., “Tesaglitazar, a PPARa/? agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats,” Toxicological Sciences, vol. 98, no. 1, pp. 63–74, 2007. View at Publisher · View at Google Scholar
  84. S. H. Tannehill-Gregg, T. P. Sanderson, D. Minnema et al., “Rodent carcinogenicity profile of the antidiabetic dual PPAR a and ? agonist muraglitazar,” Toxicological Sciences, vol. 98, no. 1, pp. 258–270, 2007. View at Publisher · View at Google Scholar
  85. E. Saez, J. Rosenfeld, A. Livolsi et al., “PPAR? signaling exacerbates mammary gland tumor development,” Genes & Development, vol. 18, no. 5, pp. 528–540, 2004. View at Publisher · View at Google Scholar
  86. L. Chen, B. M. Necela, W. Su et al., “Peroxisome proliferator-activated receptor ? promotes epithelial to mesenchymal transformation by Rho GTPase-dependent activation of ERK1/2,” Journal of Biological Chemistry, vol. 281, no. 34, pp. 24575–24587, 2006. View at Publisher · View at Google Scholar
  87. A. Bruna, M. Nicolàs, A. Muñoz, J. M. Kyriakis, and C. Caelles, “Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids,” The EMBO Journal, vol. 22, no. 22, pp. 6035–6044, 2003. View at Publisher · View at Google Scholar
  88. D. E. Clark, C. E. Poteet-Smith, J. A. Smith, and D. A. Lannigan, “Rsk2 allosterically activates estrogen receptor α by docking to the hormone-binding domain,” The EMBO Journal, vol. 20, no. 13, pp. 3484–3494, 2001. View at Publisher · View at Google Scholar
  89. Y. Yin, H. Yuan, C. Wang et al., “3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-? and promotes adipocyte differentiation,” Molecular Endocrinology, vol. 20, no. 2, pp. 268–278, 2006. View at Publisher · View at Google Scholar
  90. D. A. Sarruf, I. Iankova, A. Abella, S. Assou, S. Miard, and L. Fajas, “Cyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor γ,” Molecular and Cellular Biology, vol. 25, no. 22, pp. 9985–9995, 2005. View at Publisher · View at Google Scholar
  91. A. Abella, P. Dubus, M. Malumbres et al., “Cdk4 promotes adipogenesis through PPAR? activation,” Cell Metabolism, vol. 2, no. 4, pp. 239–249, 2005. View at Publisher · View at Google Scholar
  92. R. A. Winn, M. Van Scoyk, M. Hammond et al., “Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor ?,” Journal of Biological Chemistry, vol. 281, no. 37, pp. 26943–26950, 2006. View at Publisher · View at Google Scholar
  93. M. Akaike, W. Che, N.-L. Marmarosh et al., “The hinge-helix 1 region of peroxisome proliferator-activated receptor ?1 (PPAR?1) mediates interaction with extracellular signal-regulated kinase 5 and PPAR?1 transcriptional activation: involvement in flow-induced PPAR? activation in endothelial cells,” Molecular and Cellular Biology, vol. 24, no. 19, pp. 8691–8704, 2004. View at Publisher · View at Google Scholar
  94. J. Liu, H. Wang, Y. Zuo, and S. R. Farmer, “Functional interaction between peroxisome proliferator-activated receptor γ and β-catenin,” Molecular and Cellular Biology, vol. 26, no. 15, pp. 5827–5837, 2006. View at Publisher · View at Google Scholar
  95. M. Katoh and M. Katoh, “WNT signaling pathway and stem cell signaling network,” Clinical Cancer Research, vol. 13, no. 14, pp. 4042–4045, 2007. View at Publisher · View at Google Scholar
  96. D. Kelly, J. I. Campbell, T. P. King et al., “Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-? and RelA,” Nature Immunology, vol. 5, no. 1, pp. 104–112, 2003. View at Publisher · View at Google Scholar
  97. A. von Knethen, M. Soller, N. Tzieply et al., “PPAR?1 attenuates cytosol to membrane translocation of PKCa to desensitize monocytes/macrophages,” Journal of Cell Biology, vol. 176, no. 5, pp. 681–694, 2007. View at Publisher · View at Google Scholar
  98. E. Burgermeister and R. Seger, “MAPK kinases as nucleo-cytoplasmic shuttles for PPARγ,” Cell Cycle, vol. 6, no. 13, pp. 1539–1548, 2007. View at Google Scholar
  99. H. J. Kim, J.-Y. Hwang, H. J. Kim et al., “Expression of a peroxisome proliferator-activated receptor ?1 splice variant that was identified in human lung cancers suppresses cell death induced by cisplatin and oxidative stress,” Clinical Cancer Research, vol. 13, no. 9, pp. 2577–2583, 2007. View at Publisher · View at Google Scholar
  100. S. Nomura, A. Nakajima, S. Ishimine, N. Matsuhashi, T. Kadowaki, and M. Kaminishi, “Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues,” Journal of Experimental and Clinical Cancer Research, vol. 25, no. 3, pp. 443–448, 2006. View at Google Scholar
  101. P. Mukunyadzi, L. Ai, D. Portilla, E. L. Barnes, and C.-Y. Fan, “Expression of peroxisome proliferator-activated receptor gamma in salivary duct carcinoma: immunohistochemical analysis of 15 cases,” Modern Pathology, vol. 16, no. 12, pp. 1218–1223, 2003. View at Publisher · View at Google Scholar
  102. I. Papadaki, E. Mylona, I. Giannopoulou, S. Markaki, A. Keramopoulos, and L. Nakopoulou, “PPARγ expression in breast cancer: clinical value and correlation with ERβ,” Histopathology, vol. 46, no. 1, pp. 37–42, 2005. View at Publisher · View at Google Scholar
  103. S. Giroux, M. Tremblay, D. Bernard et al., “Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta,” Current Biology, vol. 9, no. 7, pp. 369–372, 1999. View at Publisher · View at Google Scholar
  104. L.-F. Bélanger, S. Roy, M. Tremblay et al., “Mek2 is dispensable for mouse growth and development,” Molecular and Cellular Biology, vol. 23, no. 14, pp. 4778–4787, 2003. View at Publisher · View at Google Scholar
  105. F. A. Scholl, P. A. Dumesic, and P. A. Khavari, “Effects of active MEK1 expression in vivo,” Cancer Letters, vol. 230, no. 1, pp. 1–5, 2005. View at Publisher · View at Google Scholar
  106. Y. Wan, L.-W. Chong, and R. M. Evans, “PPAR-γ regulates osteoclastogenesis in mice,” Nature Medicine, vol. 13, no. 12, pp. 1496–1503, 2007. View at Publisher · View at Google Scholar
  107. R. M. Hobbs, V. Silva-Vargas, R. Groves, and F. M. Watt, “Expression of activated MEK1 in differentiating epidermal cells is sufficient to generate hyperproliferative and inflammatory skin lesions,” Journal of Investigative Dermatology, vol. 123, no. 3, pp. 503–515, 2004. View at Publisher · View at Google Scholar
  108. F. A. Scholl, P. A. Dumesic, D. I. Barragan et al., “Mek1/2 MAPK kinases are essential for mammalian development, homeostasis, and Raf-induced hyperplasia,” Developmental Cell, vol. 12, no. 4, pp. 615–629, 2007. View at Publisher · View at Google Scholar
  109. F. A. Scholl, P. A. Dumesic, and P. A. Khavari, “Mek1 alters epidermal growth and differentiation,” Cancer Research, vol. 64, no. 17, pp. 6035–6040, 2004. View at Publisher · View at Google Scholar
  110. D. Prusty, B.-H. Park, K. E. Davis, and S. R. Farmer, “Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor γ (PPARγ) and C/EBPα gene expression during the differentiation of 3T3-L1 preadipocytes,” Journal of Biological Chemistry, vol. 277, no. 48, pp. 46226–46232, 2002. View at Publisher · View at Google Scholar
  111. C. C. Chuang, R. S. Yang, K. S. Tsai, F. M. Ho, and S. H. Liu, “Hyperglycemia enhances adipogenic induction of lipid accumulation: involvement of extracellular signal-regulated protein kinase 1/2, phosphoinositide 3-kinase/Akt, and peroxisome proliferator-activated receptor γ signaling,” Endocrinology, vol. 148, no. 9, pp. 4267–4275, 2007. View at Publisher · View at Google Scholar
  112. T. Coll, M. Jové, R. Rodríguez-Calvo et al., “Palmitate-mediated downregulation of peroxisome proliferator-activated receptor-? coactivator 1a in skeletal muscle cells involves MEK1/2 and nuclear factor-?B activation,” Diabetes, vol. 55, no. 10, pp. 2779–2787, 2006. View at Publisher · View at Google Scholar
  113. T. N. Feinstein and A. D. Linstedt, “MEK1-dependent Golgi unlinking occurs in G2 phase and promotes the G2/M cell cycle transition,” Molecular Biology of the Cell, vol. 18, no. 2, pp. 594–604, 2007. View at Google Scholar
  114. Y. D. Shaul and R. Seger, “ERK1c regulates Golgi fragmentation during mitosis,” Journal of Cell Biology, vol. 172, no. 6, pp. 885–897, 2006. View at Publisher · View at Google Scholar
  115. T. N. Feinstein and A. D. Linstedt, “Mitogen-activated protein kinase kinase 1-dependent Golgi unlinking occurs in G2 phase and promotes the G2/M cell cycle transition,” Molecular Biology of the Cell, vol. 18, no. 2, pp. 594–604, 2007. View at Publisher · View at Google Scholar
  116. D. Teis, N. Taub, R. Kurzbauer et al., “p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis,” Journal of Cell Biology, vol. 175, no. 6, pp. 861–868, 2006. View at Publisher · View at Google Scholar
  117. A. Pullikuth, E. McKinnon, H.-J. Schaeffer, and A. D. Catling, “The MEK1 scaffolding protein MP1 regulates cell spreading by integrating PAK1 and Rho signals,” Molecular and Cellular Biology, vol. 25, no. 12, pp. 5119–5133, 2005. View at Publisher · View at Google Scholar
  118. S. Torii, M. Kusakabe, T. Yamamoto, M. Maekawa, and E. Nishida, “Sef is a spatial regulator for Ras/MAP kinase signaling,” Developmental Cell, vol. 7, no. 1, pp. 33–44, 2004. View at Publisher · View at Google Scholar
  119. R. F. Morrison and S. R. Farmer, “Role of PPARγ in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis,” Journal of Biological Chemistry, vol. 274, no. 24, pp. 17088–17097, 1999. View at Publisher · View at Google Scholar
  120. J. A. Copland, L. A. Marlow, S. Kurakata et al., “Novel high-affinity PPAR? agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1,” Oncogene, vol. 25, no. 16, pp. 2304–2317, 2006. View at Publisher · View at Google Scholar
  121. M. C. Jarvis, T. J. B. Gray, and C. N. A. Palmer, “Both PPARγ and PPARδ influence sulindac sulfide-mediated p21WAF1/CIP1 upregulation in a human prostate epithelial cell line,” Oncogene, vol. 24, no. 55, pp. 8211–8215, 2005. View at Publisher · View at Google Scholar
  122. C. Zang, H. Liu, M. Waechter et al., “Dual PPARa/? ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines,” Cell Cycle, vol. 5, no. 19, pp. 2237–2243, 2006. View at Google Scholar
  123. H. Liu, C. Zang, M. H. Fenner et al., “Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARa/? ligand TZD18,” Blood, vol. 107, no. 9, pp. 3683–3692, 2006. View at Publisher · View at Google Scholar
  124. S. S. Palakurthi, H. Aktas, L. M. Grubissich, R. M. Mortensen, and J. A. Halperin, “Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation,” Cancer Research, vol. 61, no. 16, pp. 6213–6218, 2001. View at Google Scholar
  125. S. M. Weber, K. T. Chambers, K. G. Bensch, A. L. Scarim, and J. A. Corbett, “PPARγ ligands induce ER stress in pancreatic β-cells: ER stress activation results in attenuation of cytokine signaling,” American Journal of Physiology, vol. 287, no. 6, pp. E1171–E1177, 2004. View at Publisher · View at Google Scholar
  126. S. Wei, L.-F. Lin, C.-C. Yang et al., “Thiazolidinediones modulate the expression of ß-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor ?,” Molecular Pharmacology, vol. 72, no. 3, pp. 725–733, 2007. View at Publisher · View at Google Scholar
  127. J.-W. Huang, C.-W. Shiau, Y.-T. Yang et al., “Peroxisome proliferator-activated receptor ?-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells,” Molecular Pharmacology, vol. 67, no. 4, pp. 1342–1348, 2005. View at Publisher · View at Google Scholar
  128. C. Sharma, A. Pradeep, L. Wong, A. Rana, and B. Rana, “Peroxisome proliferator-activated receptor γ activation can regulate β-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway,” Journal of Biological Chemistry, vol. 279, no. 34, pp. 35583–35594, 2004. View at Publisher · View at Google Scholar
  129. B. Galusca, J. M. Dumollard, M. L. Chambonniere et al., “Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues. Possible relationship to lymph node metastasis,” Anticancer Research, vol. 24, no. 3B, pp. 1993–1997, 2004. View at Google Scholar
  130. Y. Segawa, R. Yoshimura, T. Hase et al., “Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer,” The Prostate, vol. 51, no. 2, pp. 108–116, 2002. View at Publisher · View at Google Scholar
  131. E. Mylona, A. Nomikos, C. Magkou et al., “The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma,” Histopathology, vol. 50, no. 3, pp. 338–347, 2007. View at Publisher · View at Google Scholar
  132. H. Takahashi, K. Fujita, T. Fujisawa et al., “Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties,” Cancer Science, vol. 97, no. 9, pp. 854–860, 2006. View at Publisher · View at Google Scholar
  133. T. Masuda, K. Wada, A. Nakajima et al., “Critical role of peroxisome proliferator-activated receptor ? on anoikis and invasion of squamous cell carcinoma,” Clinical Cancer Research, vol. 11, no. 11, pp. 4012–4021, 2005. View at Publisher · View at Google Scholar
  134. K. L. Schaefer, K. Wada, H. Takahashi et al., “Peroxisome proliferator-activated receptor ? inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells,” Cancer Research, vol. 65, no. 6, pp. 2251–2259, 2005. View at Publisher · View at Google Scholar
  135. C. Gensch, Y. P. Clever, C. Werner, M. Hanhoun, M. Böhm, and U. Laufs, “The PPAR-γ agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells,” Atherosclerosis, vol. 192, no. 1, pp. 67–74, 2007. View at Publisher · View at Google Scholar
  136. C.-H. Wang, M.-K. Ting, S. Verma et al., “Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus,” American Heart Journal, vol. 152, no. 6, pp. 1051.e1–1051.e8, 2006. View at Publisher · View at Google Scholar
  137. V. Chintalgattu, G. S. Harris, S. M. Akula, and L. C. Katwa, “PPAR-γ agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts,” Cardiovascular Research, vol. 74, no. 1, pp. 140–150, 2007. View at Publisher · View at Google Scholar
  138. E. Yasuda, H. Tokuda, A. Ishisaki et al., “PPAR-? ligands up-regulate basic fibroblast growth factor-induced VEGF release through amplifying SAPK/JNK activation in osteoblasts,” Biochemical and Biophysical Research Communications, vol. 328, no. 1, pp. 137–143, 2005. View at Publisher · View at Google Scholar
  139. S. Fauconnet, I. Lascombe, E. Chabannes et al., “Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells,” Journal of Biological Chemistry, vol. 277, no. 26, pp. 23534–23543, 2002. View at Publisher · View at Google Scholar
  140. F. Pistrosch, K. Herbrig, U. Oelschlaegel et al., “PPAR?-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells,” Atherosclerosis, vol. 183, no. 1, pp. 163–167, 2005. View at Publisher · View at Google Scholar
  141. E. Burgermeister, A. Schnoebelen, A. Flament et al., “A novel partial agonist of peroxisome proliferator-activated receptor-? (PPAR?) recruits PPAR?-coactivator-1a, prevents triglyceride accumulation, and potentiates insulin signaling in vitro,” Molecular Endocrinology, vol. 20, no. 4, pp. 809–830, 2006. View at Publisher · View at Google Scholar
  142. H. Kawamata, M. Tachibana, T. Fujimori, and Y. Imai, “Differentiation-inducing therapy for solid tumors,” Current Pharmaceutical Design, vol. 12, no. 3, pp. 379–385, 2006. View at Publisher · View at Google Scholar
  143. M. H. Fenner and E. Elstner, “Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer,” Expert Opinion on Investigational Drugs, vol. 14, no. 6, pp. 557–568, 2005. View at Publisher · View at Google Scholar
  144. S. Y. Lee, G. Y. Hur, K. H. Jung et al., “PPAR-? agonist increase gefitinib's antitumor activity through PTEN expression,” Lung Cancer, vol. 51, no. 3, pp. 297–301, 2006. View at Publisher · View at Google Scholar
  145. Z. Yang, R. Bagheri-Yarmand, S. Balasenthil et al., “HER2 regulation of peroxisome proliferator-activated receptor ? (PPAR?) expression and sensitivity of breast cancer cells to PPAR? ligand therapy,” Clinical Cancer Research, vol. 9, no. 8, pp. 3198–3203, 2003. View at Google Scholar
  146. D. Wang, S. A. Boerner, J. D. Winkler, and P. M. LoRusso, “Clinical experience of MEK inhibitors in cancer therapy,” Biochimica et Biophysica Acta, vol. 1773, no. 8, pp. 1248–1255, 2007. View at Publisher · View at Google Scholar
  147. W. A. Messersmith, M. Hidalgo, M. Carducci, and S. G. Eckhardt, “Novel targets in solid tumors: MEK inhibitors,” Clinical Advances in Hematology and Oncology, vol. 4, no. 11, pp. 831–836, 2006. View at Google Scholar
  148. S. V. Madhunapantula and G. P. Robertson, “Is B-Raf a good therapeutic target for melanoma and other malignancies?” Cancer Research, vol. 68, no. 1, pp. 5–8, 2008. View at Publisher · View at Google Scholar
  149. N. T. Ihle, G. Paine-Murrieta, M. I. Berggren et al., “The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts,” Molecular Cancer Therapeutics, vol. 4, no. 9, pp. 1349–1357, 2005. View at Publisher · View at Google Scholar
  150. B.-S. Herbert, V. P. Pearce, L. S. Hynan et al., “A peroxisome proliferator-activated receptor-? agonist and the p53 rescue drug CP-31398 inhibit the spontaneous immortalization of breast epithelial cells,” Cancer Research, vol. 63, no. 8, pp. 1914–1919, 2003. View at Google Scholar
  151. T. Vogt, C. Hafner, K. Bross et al., “Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors,” Cancer, vol. 98, no. 10, pp. 2251–2256, 2003. View at Publisher · View at Google Scholar
  152. A. Reichle, K. Bross, T. Vogt et al., “Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma,” Cancer, vol. 101, no. 10, pp. 2247–2256, 2004. View at Publisher · View at Google Scholar
  153. B. Kasper, A. D. Ho, and G. Egerer, “A new therapeutic approach in patients with advanced sarcoma,” International Journal of Clinical Oncology, vol. 10, no. 6, pp. 438–440, 2005. View at Publisher · View at Google Scholar
  154. R. Hennig, J. Ventura, R. Segersvard et al., “LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice,” Neoplasia, vol. 7, no. 4, pp. 417–425, 2005. View at Publisher · View at Google Scholar
  155. T. Baetz, E. Eisenhauer, L. Siu et al., “A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours,” Investigational New Drugs, vol. 25, no. 3, pp. 217–225, 2007. View at Publisher · View at Google Scholar
  156. G. K. Schwartz, A. Weitzman, E. O'Reilly et al., “Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors,” Journal of Clinical Oncology, vol. 23, no. 23, pp. 5365–5373, 2005. View at Publisher · View at Google Scholar
  157. P. Hau, L. Kunz-Schughart, U. Bogdahn et al., “Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas—a phase II study,” Oncology, vol. 73, no. 1-2, pp. 21–25, 2007. View at Publisher · View at Google Scholar
  158. M. Hedvat, A. Jain, D. A. Carson et al., “Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPAR?,” Cancer Cell, vol. 5, no. 6, pp. 565–574, 2004. View at Publisher · View at Google Scholar